

PRIOR AUTHORIZATION POLICY

POLICY: Parkinson's Disease – Zelapar Prior Authorization Policy

- Zelapar® (selegiline orally disintegrating tablets – Bausch Health)

REVIEW DATE: 03/13/2024

OVERVIEW

Zelapar, an irreversible inhibitor of monoamine oxidase, is indicated in patients with **Parkinson's disease** as an adjunct to levodopa/carbidopa among patients who exhibit deterioration in the quality of their response to this therapy.¹

Guidelines

The International Parkinson and Movement Disorder Society published an evidence-based review for treatment for motor symptoms of Parkinson's disease (2018).² The review categorically divides treatment recommendations by Parkinson's disease characteristics. Zelapar is noted to have insufficient evidence and be investigational for treatment of motor fluctuations.

POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of Zelapar. All approvals are provided for the duration noted below. Because of the specialized skills required for evaluation and diagnosis of patients treated with Zelapar as well as the monitoring required for adverse events and long-term efficacy, approval requires Zelapar to be prescribed by or in consultation with a physician who specializes in the condition being treated.

Automation: None.

RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Zelapar is recommended in those who meet the following criteria:

FDA-Approved Indication

- 1. Parkinson's Disease.** Approve for 1 year if the patient meets all of the following (A, B, C, and D):
 - A)** Patient is experiencing "off" episodes such as muscle stiffness, slow movements, or difficulty starting movements; AND
 - B)** Patient is currently receiving carbidopa/levodopa therapy; AND
 - C)** Patient has tried one of oral selegiline tablets, selegiline capsules, or rasagiline tablets and meets ONE of the following (i or ii):
 - i.** Patient had significant intolerance, according to the prescriber; OR
 - ii.** Patient has difficulty swallowing tablets or capsules; AND
 - D)** Zelapar is being prescribed by or in consultation with a neurologist.

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Zelapar is not recommended in the following situations:

1. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

REFERENCES

1. Zelapar® orally disintegrating tablets [prescribing information] Bridgewater, NJ: Bausch Health; June 2021.
2. Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease. *Mov Disord.* 2018;33(8):1248-1266.